Kunitzin-RE (1-11) L8

General Information


DRACP ID  DRACP02680

Peptide Name   Kunitzin-RE (1-11) L8

Sequence  AARIILRLRFR

Sequence Length  11

UniProt ID  L0NP29 

PubChem CID  Not available

Origin  Synthetic (Derived from Kunitzin-RE)

Type  Synthetic peptide

Classification

  

Active ACP Membrane lysis



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
RAW 264.7 Mouse leukemia Leukemia Not active up to 128 µM MTT assay 18-24 h 1

Hemolytic Activity  Human erythrocytes: <10% Hemolysis=128 µM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02680

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C63H113N23O12

Absent amino acids  CDEGHKMNPQSTVWY

Common amino acids  R

Mass  156329

Pl  12.98

Basic residues  4

Acidic residues  0

Hydrophobic residues  7

Net charge  4

Boman Index  -3340

Hydrophobicity  45.45

Aliphatic Index  160

Half Life 
  Mammalian: 4.4 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30958004

Title  Rational Design of Short Peptide Variants by Using Kunitzin-RE, an Amphibian-Derived Bioactivity Peptide, for Acquired Potent Broad-Spectrum Antimicrobial and Improved Therapeutic Potential of Commensalism Coinfection of Pathogens

Doi 10.1021/acs.jmedchem.9b00149

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.